These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 26921003)

  • 1. Expansion and angiogenic potential of mesenchymal stem cells from patients with critical limb ischemia.
    Brewster L; Robinson S; Wang R; Griffiths S; Li H; Peister A; Copland I; McDevitt T
    J Vasc Surg; 2017 Mar; 65(3):826-838.e1. PubMed ID: 26921003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversible secretome and signaling defects in diabetic mesenchymal stem cells from peripheral arterial disease patients.
    Chadid T; Morris A; Surowiec A; Robinson S; Sasaki M; Galipeau J; Pollack BP; Brewster LP
    J Vasc Surg; 2018 Dec; 68(6S):137S-151S.e2. PubMed ID: 30104096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel platelet lysate hydrogel for endothelial cell and mesenchymal stem cell-directed neovascularization.
    Robinson ST; Douglas AM; Chadid T; Kuo K; Rajabalan A; Li H; Copland IB; Barker TH; Galipeau J; Brewster LP
    Acta Biomater; 2016 May; 36():86-98. PubMed ID: 26961805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marrow changes and reduced proliferative capacity of mesenchymal stromal cells from patients with "no-option" critical limb ischemia; observations on feasibility of the autologous approach from a clinical trial.
    Mohamed SA; Duffy A; McInerney V; Krawczyk J; Hayat A; Naughton S; Finnerty A; Holohan M; Liew A; Tubassam M; Walsh SR; O'Brien T; Howard L
    Cytotherapy; 2022 Dec; 24(12):1259-1267. PubMed ID: 35999133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo efficacy of endothelial growth medium stimulated mesenchymal stem cells derived from patients with critical limb ischemia.
    Al-Rifai R; Nguyen P; Bouland N; Terryn C; Kanagaratnam L; Poitevin G; François C; Boisson-Vidal C; Sevestre MA; Tournois C
    J Transl Med; 2019 Aug; 17(1):261. PubMed ID: 31399109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of mouse bone marrow and adipose tissue mesenchymal stem cells for critical limb ischemia cell therapy.
    Nammian P; Asadi-Yousefabad SL; Daneshi S; Sheikhha MH; Tabei SMB; Razban V
    Stem Cell Res Ther; 2021 Jan; 12(1):58. PubMed ID: 33436054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower extremity arterial reconstruction for critical limb ischemia in diabetes.
    Ballotta E; Toniato A; Piatto G; Mazzalai F; Da Giau G
    J Vasc Surg; 2014 Mar; 59(3):708-19. PubMed ID: 24377943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypocellularity and insufficient expression of angiogenic factors in implanted autologous bone marrow in patients with chronic critical limb ischemia.
    Oda M; Toba K; Kato K; Ozawa T; Yanagawa T; Ikarashi N; Takayama T; Suzuki T; Hanawa H; Masuko M; Kobayashi H; Aizawa Y
    Heart Vessels; 2012 Jan; 27(1):38-45. PubMed ID: 21384270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neovascularization capacity of mesenchymal stromal cells from critical limb ischemia patients is equivalent to healthy controls.
    Gremmels H; Teraa M; Quax PH; den Ouden K; Fledderus JO; Verhaar MC
    Mol Ther; 2014 Nov; 22(11):1960-70. PubMed ID: 25174586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia.
    Powell RJ; Comerota AJ; Berceli SA; Guzman R; Henry TD; Tzeng E; Velazquez O; Marston WA; Bartel RL; Longcore A; Stern T; Watling S
    J Vasc Surg; 2011 Oct; 54(4):1032-41. PubMed ID: 21684715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet lysate as a novel serum-free media supplement for the culture of equine bone marrow-derived mesenchymal stem cells.
    Naskou MC; Sumner SM; Chocallo A; Kemelmakher H; Thoresen M; Copland I; Galipeau J; Peroni JF
    Stem Cell Res Ther; 2018 Mar; 9(1):75. PubMed ID: 29566772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The endothelial cell secretome as a novel treatment to prime adipose-derived stem cells for improved wound healing in diabetes.
    Fromer MW; Chang S; Hagaman ALR; Koko KR; Nolan RS; Zhang P; Brown SA; Carpenter JP; Caputo FJ
    J Vasc Surg; 2018 Jul; 68(1):234-244. PubMed ID: 28760584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenic effects despite limited cell survival of bone marrow-derived mesenchymal stem cells under ischemia.
    Hoffmann J; Glassford AJ; Doyle TC; Robbins RC; Schrepfer S; Pelletier MP
    Thorac Cardiovasc Surg; 2010 Apr; 58(3):136-42. PubMed ID: 20379963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic Mesenchymal Stem Cells Are Ineffective for Improving Limb Ischemia Due to Their Impaired Angiogenic Capability.
    Kim H; Han JW; Lee JY; Choi YJ; Sohn YD; Song M; Yoon YS
    Cell Transplant; 2015; 24(8):1571-84. PubMed ID: 25008576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous bone marrow mesenchymal stromal cell therapy for "no-option" critical limb ischemia is limited by karyotype abnormalities.
    Mohamed SA; Howard L; McInerney V; Hayat A; Krawczyk J; Naughton S; Finnerty A; Holohan M; Duffy A; Moloney T; Kavanagh E; Burke P; Liew A; Tubassam M; Walsh SR; O'Brien T
    Cytotherapy; 2020 Jun; 22(6):313-321. PubMed ID: 32273232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous Platelet Lysate Does Not Enhance Chondrogenic Differentiation of Equine Bone Marrow-Derived Mesenchymal Stromal Cells Despite Increased TGF-β1 Concentration.
    Chapman HS; Gale AL; Dodson ME; Linardi RL; Ortved KF
    Stem Cells Dev; 2020 Feb; 29(3):144-155. PubMed ID: 31802705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of the MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia in Subjects with Severe Peripheral Arterial Disease (MOBILE) trial investigating autologous bone marrow cell therapy for critical limb ischemia.
    Wang SK; Green LA; Motaganahalli RL; Wilson MG; Fajardo A; Murphy MP
    J Vasc Surg; 2017 Jun; 65(6):1850-1857.e2. PubMed ID: 28390770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Human Platelet Lysate in Differentiation of Wharton's Jelly Derived Mesenchymal Stem Cells.
    Vennila R; Raja Sundari M Sundaram ; Selvaraj S; Srinivasan P; Pathak S; Rupert S; Rajagopal S
    Endocr Metab Immune Disord Drug Targets; 2019; 19(8):1177-1191. PubMed ID: 30819088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of the SAIL trial for intramuscular injection of allogeneic mesenchymal stromal cells in no-option critical limb ischemia.
    Wijnand JGJ; Teraa M; Gremmels H; van Rhijn-Brouwer FCC; de Borst GJ; Verhaar MC;
    J Vasc Surg; 2018 Feb; 67(2):656-661. PubMed ID: 29242062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: a pilot study.
    Lee HC; An SG; Lee HW; Park JS; Cha KS; Hong TJ; Park JH; Lee SY; Kim SP; Kim YD; Chung SW; Bae YC; Shin YB; Kim JI; Jung JS
    Circ J; 2012; 76(7):1750-60. PubMed ID: 22498564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.